Mechanistically, on the one hand, Slc6a6 acts as a central regulator of antioxidant defense via both intrinsic regulatory mechanisms and taurine-dependent pathways to reduce intracellular reactive oxygen species (ROS), thereby protecting cancer cells from oxidative damage; on the other hand, Slc6a6 directly interacts with the cell cycle regulator Rprd1b to accelerate the cell cycle. The gene discussed is RPRD1B; the disease is cancer.